Literature DB >> 20620425

The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock.

Andre Pascal Kengne1, Fiona Turnbull, Stephen MacMahon.   

Abstract

The global population of individuals with diabetes is important and rapidly growing. Because of the link between diabetes and cardiovascular disease (CVD), it is expected that diabetes will be an important driver of the future burden of CVD around the world. A connection between diabetes and CVD was suspected as earlier as in the mid 19th century. However, CVD in diabetes received less attention until the advent in the 20th century of treatments that allowed people with diabetes to live long enough to experience CVD. Since then the relationship between diabetes and CVD has been extensively investigated and characterised. The present article outlines the important contribution the Framingham Heart Study has made to the recognition of diabetes as a cardiovascular risk factor and the way in which the study has informed the association between other risk factors and CVD in the presence of diabetes, the changing pattern of the risk with time, and the quantification of CVD risk in the presence of diabetes. Through this contribution, Framingham has largely influenced our understanding of CVD in people with diabetes. Lines of investigation regarding cardiovascular health in this population are still wide open, and the Framingham Study continues to be part of this journey. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20620425     DOI: 10.1016/j.pcad.2010.02.010

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  8 in total

1.  Rosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells.

Authors:  Clintoria R Williams; Xianghuai Lu; Roy L Sutliff; C Michael Hart
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-09       Impact factor: 4.249

Review 2.  The ADVANCE cardiovascular risk model and current strategies for cardiovascular disease risk evaluation in people with diabetes.

Authors:  Andre Pascal Kengne
Journal:  Cardiovasc J Afr       Date:  2013 Oct-Nov       Impact factor: 1.167

3.  Use of antidiabetic and antidepressant drugs is associated with increased risk of myocardial infarction: a nationwide register study.

Authors:  K Rådholm; A-B Wiréhn; J Chalmers; C J Östgren
Journal:  Diabet Med       Date:  2015-07-02       Impact factor: 4.359

4.  Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study.

Authors:  Brane Loncarevic; Danijela Trifunovic; Ivan Soldatovic; Bosiljka Vujisic-Tesic
Journal:  BMC Cardiovasc Disord       Date:  2016-11-29       Impact factor: 2.298

5.  Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study.

Authors:  Kennosuke Ohashi; Takeshi Hayashi; Yui Watanabe; Koichiro Hara; Rikako Ukichi; Hiroshi Asano; Hirofumi Suzuki; Kenji Yamashiro; Katsuyoshi Tojo; Masaya Sakamoto; Kazunori Utsunomiya
Journal:  J Clin Med Res       Date:  2017-12-01

Review 6.  Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients.

Authors:  Jovana Nikolajević Starčević; Miodrag Janić; Mišo Šabovič
Journal:  Int J Mol Sci       Date:  2019-03-09       Impact factor: 5.923

7.  Staged complete revascularization or culprit-only percutaneous coronary intervention for multivessel coronary artery disease in patients with ST-segment elevation myocardial infarction and diabetes.

Authors:  Kongyong Cui; Shuzheng Lyu; Hong Liu; Xiantao Song; Fei Yuan; Feng Xu; Min Zhang; Wei Wang; Mingduo Zhang; Dongfeng Zhang; Jinfan Tian
Journal:  Cardiovasc Diabetol       Date:  2019-09-17       Impact factor: 9.951

8.  A systematic overview of prospective cohort studies of cardiovascular disease in sub-Saharan Africa: reply to Bovet et al., and Gao et al.

Authors:  Andre Pascal Kengne; Bongani M Mayosi
Journal:  Cardiovasc J Afr       Date:  2012-09       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.